Inside Pharma's Patent Battleground: The Policy Changes Reshaping Generic and Biosimilar Competition

Recent changes at the U.S. Patent and Trademark Office are making it harder to challenge pharmaceutical patents, raising concerns that slower generic and biosimilar competition could undermine efforts to lower drug costs while strengthening protections for brand-name innovators.